Shaoyu Liu

Dr. Shaoyu Liu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2024 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
LLLifang Liu
Lifang Liu
JZJiawei Zhong
Jiawei Zhong
ZZZiqi Zhang
Ziqi Zhang
XYXiaoting Ye
Xiaoting Ye
XWXinlu Wang
Xinlu Wang
ZZZhanwen Zhang
Zhanwen Zhang

24 June 2024 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
SLShaoyu Liu
Shaoyu Liu
JZJiawei Zhong
Jiawei Zhong
ZZZiqi Zhang
Ziqi Zhang
RZRuiyue Zhao
Ruiyue Zhao
QYQingsong Yan
Qingsong Yan
XWXinlu Wang
Xinlu Wang

1 October 2024 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
SLShaoyu Liu
Shaoyu Liu
ZZZiqi Zhang
Ziqi Zhang
JZJiawei Zhong
Jiawei Zhong
HZHuizhen Zhong
Huizhen Zhong
YFYimin Fu
Yimin Fu
XWXinlu Wang
Xinlu Wang
Fibroblast activation protein (FAP) has gained attention as a promising molecular target with potential utility for cancer diagnosis and therapy. [68Ga]Ga-labeled FAP-targeting peptides have been successfully applied to positron emission tomography (PET) imaging of various tumor types. To meet the applicable demand for peptide-based FAP tracers with high patient throughput, we herein report the radiosynthesis, preclinical evaluation, and the first-in-human imaging of a novel [18F]F-labeled FAP-targeting peptide. [18F]AlF-FAP-NUR was automatedly prepared within 45 min with a non-decay corrected radiochemical yield of 18.73 ± 4.25% (n = 3). Compared to [68Ga]Ga-FAP-2286, the [18F]F-labeled peptide demonstrated more rapid, higher levels of cellular uptake and internalization, and lower levels of cellular efflux in HT1080-FAP cells. Micro-PET imaging and biodistribution studies conducted on xenograft mice models revealed a similar distribution pattern between the two tracers. However, [18F]AlF-FAP-NUR demonstrated significantly higher tumor-specific uptake resulting in improved Tumor-Background Ratios (TBRs). In the patients, a significant accumulation of [18F]AlF-FAP-NUR was found in the primary tumor. High uptake of the tracer within the bladder indicated that its major route of excretion was through urine. Based on the physical imaging properties and longer half-life of [18F]F, [18F]AlF-FAP-NUR exhibited promising characteristics such as enhanced tumor-specific accumulation and elevated TBRs, which made it a viable candidate for further clinical investigation. www.Chictr.org.cn , ChiCTR2300076976 Retrospectively registered 25 October 2023. at, URL: https://www.chictr.org.cn/showproj.html?proj=206753 .

29 April 2026 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
RZRuiyue Zhao
Ruiyue Zhao
YDYuling Deng
Yuling Deng
WJWenbin Jin
Wenbin Jin
MXMingheng Xu
Mingheng Xu
WLWanmei Liang
Wanmei Liang
XWXinlu Wang
Xinlu Wang

5 February 2024 in Research Square
Verified
Preprint
Open access
PDF file
ZZZiqi Zhang
Ziqi Zhang
JZJiawei Zhong
Jiawei Zhong
LLLifang Liu
Lifang Liu
XYXiaoting Ye
Xiaoting Ye
XWXin-Lu Wang
Xin-Lu Wang
SLShaoyu Liu
Shaoyu Liu
Background Fibroblast activation protein (FAP) has gained attention as a promising molecular target with potential utility for cancer diagnosis and therapy. 68Ga-labeled FAP-targeting peptides have been successfully applied to positron emission tomography (PET) imaging of various tumor types. To meet the applicable demand for peptide-based FAP tracers with high patient throughput, we herein report the radiosynthesis, preclinical evaluation, and the first-in-human imaging of a novel 18F-labeled FAP-targeting peptide. Methods Al18F-FAP-NUR was radiolabeled with 18F using an Al18F complex on a modified GE TRACERlab FXFN synthesis platform. The 18F-labeled peptide was evaluated against 68Ga-FAP-2286, a 68Ga-labeled FAP-targeting peptide, in biochemical and cellular assays, ex vivo biodistribution studies, and in vivo micro-PET imaging. Additionally, successful first-in-human imaging of the 18F-labeled peptide was performed in two patients with breast cancer and lung cancer, respectively. Results Al18F-FAP-NUR was automatedly prepared within 45 min with a non-decay corrected radiochemical yield of 18.73 ± 4.25% (n = 3). Compared to 68Ga-FAP-2286, the 18F-labeled peptide demonstrated more rapid, higher levels of cellular uptake and internalization, and lower levels of cellular efflux in HT1080-FAP cells. Micro-PET imaging and biodistribution studies conducted on xenograft mice models revealed a similar distribution pattern between the two tracers. However, Al18F-FAP-NUR demonstrated significantly higher tumor-specific uptake resulting in improved Tumor-Background Ratios (TBRs). In the patients, a significant accumulation of Al18F-FAP-NUR was found in the primary tumor. High uptake of the tracer within the bladder indicated that its major route of excretion was through urine. Conclusion Based on the physical imaging properties and longer half-life of 18F, Al18F-FAP-NUR exhibited promising characteristics such as enhanced tumor-specific accumulation and elevated TBRs, which made it a viable candidate for further clinical investigation.